Teva Pharmaceutical Industries is a global leader in generic and specialty pharmaceuticals. The company develops, manufactures, and markets a wide range of medications, including generic drugs, active pharmaceutical ingredients, and specialty treatments for various conditions. Major business segments include generics, specialty medicines, and over-the-counter products. The primary revenue sources are sales from generic pharmaceuticals and specialty treatments, with a focus on therapeutic areas such as central nervous system disorders, pain management, and respiratory diseases.
Teva's investment profile is characterized by a focus on stability rather than aggressive growth. The company has faced challenges in revenue and earnings, making it more suitable for value investors seeking potential recovery rather than high growth. The stock may appeal to those looking for a balanced approach, given its established market presence and ongoing efforts to stabilize operations.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-31 | Sell | Hold | Weak revenue growth raises uncertainty despite recent price momentum. |
| 2026-07-12 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-25 | Sell | Hold | Mixed performance; fundamentals show weakness and uncertainty. |
| 2026-06-21 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-06-13 | Sell | Hold | Weak revenue growth raises concerns despite positive EPS surprise. |
| 2026-06-03 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-08 | — | Hold | Mixed performance; fundamentals show weakness and uncertainty. |
| 2026-05-08 | Hold | Hold | Компания показывает позитивную динамику на длительном горизонте, однако недавнее снижение выручки вызывает опасения. Рекомендуется удерживать акции до прояснения ситуации. |
| 2026-02-15 | — | Hold | Компания демонстрирует значительный рост за последние 120 дней, однако недавняя волатильность и отсутствие данных по EPS и выручке вызывают опасения. Рекомендуется удерживать акции до получения более ясной финансовой инф |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-09 | Leerink Partners | Update | — → 45 | 36.76 |
| 2026-09-04 | UBS | Target Raised | — → 48 | 36.62 |
| 2026-08-12 | Barclays | Target Raised | 40 → 42 | 36.48 |
| 2026-07-28 | Piper Sandler | Target Raised | 42 → 44 | 31.08 |
| 2026-05-06 | Barclays | Target Raised | 38 → 40 | 35.86 |
| 2026-04-30 | Piper Sandler | Target Raised | 41 → 42 | 35.38 |
| 2026-04-30 | UBS | Target Raised | 36 → 42 | 35.38 |
| 2026-03-04 | Piper Sandler | Target Raised | — → 41 | 32.64 |
| 2026-01-30 | Barclays | Target Raised | 35 → 38 | 33.07 |
| 2026-01-29 | Scotiabank | Target Raised | 35 → 40 | 32.895 |
| 2026-01-07 | Truist Financial | Target Raised | 32 → 36 | 32.11 |
| 2026-01-06 | Jefferies | Target Raised | — → 40 | 31 |
| 2025-12-22 | Piper Sandler | Target Raised | 30 → 40 | 30.35 |
| 2025-12-18 | Goldman Sachs | Target Raised | 31 → 35 | 30.06 |
